Curated Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Curated Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.8K	Buy	+47,715	New	+$7.08M	0.01%	647
2025 Q1	–	Sell	-2,704	Closed	-$369K	–	159
2024 Q4	$369K	Buy	2,704 +33	+1%	+$4.08K	0.04%	105
2024 Q3	$308K	Hold	2,671	–	–	0.04%	105
2024 Q2	$368K	Buy	+2,671	New	+$366K	0.05%	94
2024 Q1	–	Sell	-2,841	Closed	-$388K	–	227
2023 Q4	$374K	Buy	2,841 +214	+8%	+$24.6K	0.06%	102
2023 Q3	$296K	Buy	+2,627	New	+$277K	0.05%	106

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Curated Wealth Partners's NBIX Position: Q2 2026 in Review

Curated Wealth Partners opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 47,715 shares worth $73.8K. The stake represents 0.01% of the portfolio and ranks #647 among its holdings. This is a return to the name: Curated Wealth Partners previously reported a position in NBIX as recently as Q4 2024.

Curated Wealth Partners first reported a position in NBIX in Q3 2023 and has held it in 6 quarters since. The position peaked at $374K in Q4 2023. 116 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Curated Wealth Partners held 47,715 shares of Neurocrine Biosciences worth $73.8K as of Q2 2026.
Neurocrine Biosciences was a new Curated Wealth Partners position in Q2 2026.
Neurocrine Biosciences made up 0.01% of Curated Wealth Partners's portfolio in Q2 2026, its #647 holding.
Curated Wealth Partners first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 6 quarters since.
Curated Wealth Partners's Neurocrine Biosciences position peaked at $374K in Q4 2023.
116 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Curated Wealth Partners's 13F filing for Q2 2026, filed 13 Jul 2026.